Download Image
    
Share
  
Post
HuMax-IL8 for COVID-19
1 study with 43 patients
Hospital Icon Control
Hospital Icon HuMax-IL8 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 HuMax-IL8 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -6% Mortality -6% RCTs -6% Late -6% FavorsHuMax-IL8 Favorscontrol
May 22
 Stein et al., NCT04347226 A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19
6% higher mortality (p=1), 100% higher ICU admission (p=0.59), and 107% slower improvement (p=0.08). RCT 43 hospitalized patients in the USA showing no significant benefit with HuMax-IL8 (BMS-986253) treatment.